Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Revenue Recognition - Contract Assets and Liabilities (Details)

v3.22.1
Revenue Recognition - Contract Assets and Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Contract with Customer, Asset, Net [Abstract]    
Current pharma contract assets $ 1,643 $ 1,738
Long-term pharma contract assets 261 236
Total pharma contract assets 1,904 1,974
Capitalized Contract Cost [Abstract]    
Current pharma capitalized commissions 168 109
Long-term pharma capitalized commissions 972 882
Total pharma capitalized commissions 1,140 991
Contract with Customer, Liability [Abstract]    
Current pharma contract liabilities 6,119 5,192
Long-term pharma contract liabilities 1,081 917
Total pharma contract liabilities $ 7,200 $ 6,109